NASDAQ:PHAR Pharming Group (PHAR) Stock Price, News & Analysis $10.77 -0.49 (-4.35%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$10.60 -0.17 (-1.56%) As of 06:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Pharming Group Stock (NASDAQ:PHAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharming Group alerts:Sign Up Key Stats Today's Range$10.65▼$11.0650-Day Range$9.82▼$13.4752-Week Range$9.62▼$21.34Volume28,597 shsAverage Volume28,906 shsMarket Capitalization$762.30 millionP/E Ratio89.75Dividend YieldN/APrice Target$38.67Consensus RatingHold Company Overview Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options. Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling. Ruconest is marketed in the United States, Europe and other international markets, subject to applicable regulatory approvals. The company also commercializes Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, or APDS, a rare primary immunodeficiency. Joenja was developed by Orchard Therapeutics, which Pharming acquired in 2023, and has expanded Pharming’s rare-disease portfolio beyond hereditary angioedema. Pharming continues to pursue additional indications and geographic approvals for its products through regulatory and commercial activities in North America, Europe and other selected markets.AI Generated. May Contain Errors. Read More Pharming Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScorePHAR MarketRank™: Pharming Group scored higher than 87% of companies evaluated by MarketBeat, and ranked 68th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingPharming Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialPharming Group has a consensus price target of $38.67, representing about 259.0% upside from its current price of $10.77.Amount of Analyst CoveragePharming Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pharming Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth13.64% Earnings GrowthEarnings for Pharming Group are expected to grow by 13.64% in the coming year, from $0.22 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is 89.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is 89.75, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.02.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pharming Group's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Pharming Group has been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently decreased by 65.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.60 News SentimentPharming Group has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Pharming Group this week, compared to 3 articles on an average week.Search Interest2 people have searched for PHAR on MarketBeat in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock.Percentage Held by Insiders2.07% of the stock of Pharming Group is held by insiders.Percentage Held by Institutions0.03% of the stock of Pharming Group is held by institutions.Read more about Pharming Group's insider trading history. Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAR Stock News HeadlinesPharming Group N.V. Announces Positive Phase II Topline Data For Leniolisib In PIDs With Immune Dysregulation Accepted As Late-Breaking Abstract At ESID 2026September 22 at 9:05 AM | marketscreener.comMPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026September 22 at 9:05 AM | finance.yahoo.comHas Dylan Jovine lost his mind?SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation. But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly. An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151.September 24 at 1:00 AM | Behind the Markets (Ad)FY2027 EPS Estimates for Pharming Group Cut by HC WainwrightSeptember 18, 2026 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) versus Pharming Group (NASDAQ:PHAR) Financial ComparisonSeptember 17, 2026 | americanbankingnews.comFY2026 EPS Estimates for Pharming Group Cut by HC WainwrightSeptember 17, 2026 | americanbankingnews.comPharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?September 16, 2026 | insidermonkey.comHC Wainwright Reiterates Buy Rating for Pharming Group (NASDAQ:PHAR)September 16, 2026 | americanbankingnews.comSee More Headlines PHAR Stock Analysis - Frequently Asked Questions How have PHAR shares performed this year? Pharming Group's stock was trading at $17.67 at the beginning of 2026. Since then, PHAR shares have decreased by 39.0% and is now trading at $10.77. How were Pharming Group's earnings last quarter? Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) announced its earnings results on Thursday, July, 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.04. Pharming Group had a net margin of 2.51% and a trailing twelve-month return on equity of 3.40%. Read the conference call transcript. When did Pharming Group IPO? Pharming Group (PHAR) raised $0 in an initial public offering on Wednesday, December 23rd 2020. The company issued 899,802 shares at $0.00 per share. Who are Pharming Group's major shareholders? Top institutional investors of Pharming Group include MAC Alpha Capital Management LP (3.03%). How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharming Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), Meta Platforms (META), NVIDIA (NVDA), Applied DNA Sciences (APDN), Costco Wholesale (COST). Company Calendar Last Earnings7/30/2026Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PHAR's financial health is in the Red zone, according to TradeSmith. PHAR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHAR CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees407Year Founded1988Price Target and Rating Average Price Target for Pharming Group$38.67 High Price Target$41.00 Low Price Target$37.00 Potential Upside/Downside+259.0%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio89.75 Forward P/E Ratio48.95 P/E GrowthN/ANet Income$2.85 million Net Margins2.51% Pretax Margin4.31% Return on Equity3.40% Return on Assets1.90% Debt Debt-to-Equity Ratio0.34 Current Ratio3.01 Quick Ratio2.31 Sales & Book Value Annual Sales$376.13 million Price / Sales2.03 Cash Flow$0.19 per share Price / Cash Flow56.14 Book Value$3.95 per share Price / Book2.73Miscellaneous Outstanding Shares70,780,000Free Float69,313,000Market Cap$762.30 million OptionableNot Optionable Beta0.01 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:PHAR) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
